MB

Michael Byrnes

Former CFO

eFFECTOR Therapeutics

Therapeutic Areas

eFFECTOR Therapeutics Pipeline

DrugIndicationPhase
ZotatifinKRAS-mutant NSCLC; ER+ Breast CancerPhase 1b/2
TomivosertibMetastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2